Top Markets
#1 Black Phoenix Black Phoenix +21,392.78%
#2 Nesa Nesa +679.37%
#3 Cortex Cortex +92.11%
#4 Ontology Gas Ontology Gas +77.46%
#5 Kinesis Silver Kinesis Silver +54.91%
#6 Magma Finance Magma Finance +25.67%
#7 Biconomy Biconomy +25.24%
#8 QuantixAI QuantixAI +23.07%
#9 EXOD EXOD +22.78%
#10 SAFEcoin SAFEcoin +20.88%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Oruka Therapeutics, Inc. Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA
Rank in Stocks #3140
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Share Price
$101.34
Market Cap
$6.11B
Change (1 day)
-0.47%
Change (1 year)
584.26%
Country
US
Trade Oruka Therapeutics, Inc. (ORKA)

Category

Healthcare
P/E ratio for Oruka Therapeutics, Inc. (ORKA)
P/E ratio as of 2026 TTM: 0
According to Oruka Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Oruka Therapeutics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.